Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Tanner HensonDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.ORCID 0009-0006-0166-0694
Alessandra ArizziDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.
Conary MeyerDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.
David WangDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.ORCID 0000-0001-6274-9947
Neona M LoweDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.
Yongheng WangDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.
Keerthana AnandaDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.
Randy P CarneyDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.ORCID 0000-0001-8193-1664
Aijun WangDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.ORCID 0000-0002-2985-3627
Cheemeng TanDepartment of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.ORCID 0000-0003-1049-1192
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Engineering and dissecting the synthetic non-dividing-but-active state of hybrid cell-materialsR35GM142788 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Cheemeng Tan · 2021 to 2026
$2.7M
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida TherapyR01NS115860 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FARMER, DIANA LEE, WANG, AIJUN · 2020 to 2024
$2.5M
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biologyR01EB034279 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Randy Carney, Cheemeng Tan · 2023 to 2026
$2.5M
Homogenized, engineered extracellular vesicles for intracranial targetingR01EB033389 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Randy Carney, Aijun Wang · 2023 to 2026
$2.4M
Engineering an extracellular vesicle-based targeted regenerative nanotherapeutic for multiple sclerosisR01NS131538 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aijun Wang · 2024 to 2026
$1.4M
Engineered extracellular vesicles as a targeted drug delivery system for multiple sclerosisF31NS120590 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MIZENKO, RACHEL REGINA · 2022 to 2024
The many surface proteins on extracellular vesicles (EVs) allow them to target recipient cells and modulate cellular responses. Despite their importance, relating surface protein and EV function is challenging due to surface protein heterogeneity. Here, we create a bottom-up, cell-free protein-synthesis platform to engineer artificial nanovesicles (ANVs) that display different EV surface protein domains. The platform is termed VESSEL (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Prototyping Minimal Extracellular Vesicle Mimetics Using Cell-Free Synthesis. · full record | OpenQuestion